Welcome to our dedicated page for Theravance Bioph news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Bioph stock.
Theravance Biopharma Inc (NASDAQ: TBPH) drives innovation in organ-selective medicines, with this dedicated news hub providing essential updates for stakeholders. Access verified press releases and objective reporting on clinical developments, regulatory milestones, and strategic partnerships.
This comprehensive resource delivers timely information about TBPH's respiratory therapies like YUPELRI® and emerging pipeline candidates. Track progress across key areas including COPD treatment advancements, neurological disorder research, and collaborative drug development initiatives.
Users can expect updates covering FDA submissions, clinical trial outcomes, financial results, and scientific publications. All content undergoes rigorous verification to ensure alignment with corporate disclosures and regulatory standards.
Bookmark this page for direct access to primary source materials and distilled insights into Theravance Biopharma's progress in biopharmaceutical innovation. Regularly refreshed content supports informed decision-making for investors and industry observers.
Theravance Biopharma (NASDAQ: TBPH) announced a proposed public offering of its ordinary shares, which includes a 30-day underwriters' option for an additional 15% of shares. The offering is contingent upon market conditions. Proceeds will primarily fund the development of ampreloxetine for neurogenic orthostatic hypotension and izencitinib for ulcerative colitis and Crohn's disease. Remaining funds will support other clinical initiatives and working capital. The offering is subject to customary closing conditions, and no assurance can be given regarding its completion.
Theravance Biopharma (NASDAQ: TBPH) announced top-line results from its Phase 2 study of 3 mg once-daily nezulcitinib for hospitalized COVID-19 patients. Despite not meeting the primary endpoint, the trial showed a favorable trend in 28-day all-cause mortality (6 deaths in nezulcitinib group vs. 13 in placebo, HR: 0.42, p=0.08). The trial involved 210 patients and demonstrated good tolerability with lower adverse events compared to the placebo. The company plans to consult with regulatory agencies on further study protocols.
Theravance Biopharma, listed on NASDAQ as TBPH, will participate in the Bank of America 2021 Healthcare Conference on May 13 at 2:45 p.m. ET. CEO Rick E Winningham will present during the event, which can be accessed via a webcast on the company's website. The presentation will focus on the company's mission to develop organ-selective medicines aimed at improving patient outcomes in serious illnesses, particularly in inflammation and immunology.
Theravance Biopharma (TBPH) reported Q1 2021 total revenue of $14.3 million, a decrease of $5.6 million YOY, attributed mainly to collaboration revenue from Viatris. While YUPELRI's market share grew to 19%, overall net sales faced a slight decline. R&D expenses increased to $67.6 million, leading to an operating loss of $83.9 million. The company anticipates full-year R&D expenses between $195 million and $225 million. Notable upcoming clinical milestones include results for nezulcitinib and izencitinib trials expected in Q2 and Q3 2021.
Theravance Biopharma (NASDAQ: TBPH) will announce its first quarter 2021 financial results on May 4, 2021, after market close. A conference call will follow at 5:00 p.m. ET. The company focuses on organ-selective medicines and aims to improve patient lives. Its notable product includes YUPELRI® for COPD. This update will provide critical insights into financial performance and business developments crucial for investors.
Theravance Biopharma (NASDAQ: TBPH) will participate in a pre-recorded Fireside Chat at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021. Interested investors can access the webcast through the 'Investors' section of Theravance's website, specifically under 'Events and Presentations.' A replay of the event will be available for at least 30 days. Theravance Biopharma focuses on developing organ-selective medicines, particularly in the areas of inflammation and immunology, aiming to improve patient outcomes.
Theravance Biopharma (TBPH) announced its financial results for Q4 and full year 2020, highlighting 159% year-over-year sales growth for YUPELRI, now capturing 18.6% of the nebulized COPD market. Despite this growth, total revenue for Q4 decreased by $10.8 million to $18.7 million, with a full year revenue of $71.9 million. Operating loss increased to $76.5 million in Q4. The company is optimistic about ongoing clinical trials, particularly for TD-0903 in COVID-19 patients, and expects significant milestones in 2021, including data releases for ongoing studies. Cash reserves stood at $292.9 million.
Theravance Biopharma (NASDAQ: TBPH) announced its participation in key investor events. Management will engage in a Fireside Chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 24 at 12:00 p.m. ET. Additionally, Richard A. Graham will join the GI/Microbiome Panel at the Cowen 41st Annual Cowen Conference on March 2 at 11:10 a.m. ET. Interested investors can access the webcast via the "Investors" section on Theravance's website, where replays will be available for 30 days.
Theravance Biopharma (NASDAQ: TBPH) will announce its fourth quarter and full year 2020 financial results on February 23, 2021, after market close. A conference call and webcast are scheduled for 5:00 p.m. ET. The company focuses on organ-selective medicines, targeting inflammation and immunology. Notably, it has developed YUPELRI®, an inhalation solution for COPD. The announcement may impact investors keen on financial performance metrics and future growth prospects.
Theravance Biopharma (NASDAQ: TBPH) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 2:00 p.m. ET. The presentation will focus on the company's commitment to developing organ-selective medicines aimed at treating serious illnesses, particularly in inflammation and immunology. Investors can access the webcast on the company's website and the replay will be available for 30 days. Theravance's research includes the approved YUPELRI® inhalation solution for COPD, showcasing its focus on patient-centered drug development.
